OEM Partnerships Burst Diagnostics specializes in custom assay development and point of need testing, delivering lab-quality performance. This positions the company to partner with device manufacturers and clinical labs to co-develop rapid immunoassays using Burst’s CaDI platform, enabling white-label or joint development arrangements to accelerate time-to-market and expand product offerings.

CaDI Platform The CaDI platform enables simplified enzyme-amplified immunoassays into rapid, low-cost formats. This capability can be licensed or embedded as the foundation for customers building their own at home or point-of-care tests, while Burst provides assay design, optimization, and manufacturing support to shorten development cycles.

Channel Opportunities With a focus on at home and point-of-care testing, Burst Diagnostics can target telehealth providers, home health services, urgent care clinics, pharmacies, and mid-sized laboratories. Build channel partnerships with distributors and healthcare retailers to reach end users with ready-to-deploy assays and ongoing support.

Leadership Growth Recent board appointments of Mary Gunn and Larry Jia underscore governance and growth strategy, providing a credible entry point for strategic partnerships and potential investors. Leverage this leadership as a talking point when approaching large diagnostics firms and funding sources to secure collaborations and capital.

Lean Growth Engine Operating with 11-50 employees and revenue between 1 and 10 million, Burst Diagnostics offers a lean, scalable model ideal for mid-market collaborations. Position as a nimble partner that can augment larger diagnostics players with rapid assay development capabilities and avoid sizable internal R&D overhead.